The Africa anti-rheumatic drugs market is expected to grow at a CAGR of 3.27% from an initial value of US$1,451.120 million in 2021 and is estimated to reach a market size of US$1,817.221 million in 2028.
Anti-rheumatic drugs are substances that are administered to treat rheumatoid arthritis, among other diseases like gout, lupus, osteoarthritis and so on. The market in the region is expected to see growth due to the growing geriatric population along with the presence of a fair share of pharmaceutical companies in the region.
Growth factors:
The anti-rheumatic drugs market in Africa is expected to be considerably driven due to the prevalence of rheumatic diseases in the region.
According to a study published in April 2021, under the name, “Rheumatic diseases in Africa”, it was estimated that about 4.3 million individuals in the African region suffered from rheumatoid arthritis with the prevalence in individual countries estimated to be in the range of 0.06% to 3.4%. Thus, this extensive prevalence of these diseases in the region is expected to drive the demand for anti-0rheumatic drugs, in turn, driving the regional market.The rising old-age population in the country is expected to be one of the key factors contributing to the market growth in the region.
This is because the elderly population is more susceptible to the diseases and conditions for which these rheumatic drugs act as an aid. According to the United States Census Bureau, the population of Africa in the age bracket of 60 and above was recorded at 74.4 million and according to the projections by the Bureau, this figure is expected to rise to about 235.1 million by 2050, thus, showing a growth of more than 300% of the initial figure. Along with that, the proportion of people of age 60 and above is also projected to increase from 2020 to 2050. This steady rise in the geriatric population in the region is thus expected to drive the market for anti-rheumatic drugs in the African region.Key development:
- In January 2023, the DSI (Department of Science and Innovation) and IPASA (Innovative Pharmaceutical Association of South Africa) collaborated with the SAMRC (South African Medical Research Council) in order to enhance the R&D capability in South Africa along with the commercialization of novel and innovative health solutions and boosting the pharmaceutical sector in the country. The IPASA is an association that consists of key market players like Merck, Novartis, Pfizer, and Roche, to name a few.
- Pfizer Nigeria launched a patient assistance program, “Project Afya” in 2019 which focuses on improving access to life-saving medication and treatment of rheumatoid arthritis for people living in rural and low-income areas.
Based on country, theAfrica anti-rheumatic drug market is divided into South Africa, Nigeria, Algeria, Kenya, Tunisia, and others.
South African market is expected to hold a significant share in the African anti-rheumatic drug market.Market Segmentation:
By Type Of Disease
- Osteoarthritis
- Rheumatoid Arthritis
- Gout
- Lupus
- Others
By Drug Class
- Non-Steroid anti-inflammatory agents (NSAIDs)
- Corticosteroids
- Disease-modifying anti-rheumatic drugs (DMARDs)
- Methotrexate
- Sulfasalazine
- Hydroxychloroquine
- Leflunomide
- Biologic DMARDs
- Others
By Sales Channel
- Prescription
- Over-the-counter (OTC)
By Country
- South Africa
- Nigeria
- Algeria
- Kenya
- Tunisia
- Others
Table of Contents
1. INTRODUCTION1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Research Design
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. AFRICA ANTI-RHEUMATIC DRUG MARKET, BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. AFRICA ANTI-RHEUMATIC DRUG MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Non-Steroid anti-inflammatory agents (NSAIDs)
6.3. Corticosteroids
6.4. Disease-modifying anti-rheumatic drugs (DMARDs)
6.4.1. Methotrexate
6.4.2. Sulfasalazine
6.4.3. Hydroxychloroquine
6.4.4. Leflunomide
6.4.5. Biologic DMARDs
6.5. Others
7. AFRICA ANTI-RHEUMATIC DRUG MARKET, BY TYPE OF MOLECULE
7.1. Introduction
7.2. Pharmaceuticals
7.3. Biopharmaceuticals
8. AFRICA ANTI-RHEUMATIC DRUG MARKET, BY SALES CHANNEL
8.1. Introduction
8.2. Prescription
8.3. Over-the-counter (OTC)
9. AFRICA ANTI-RHEUMATIC DRUG MARKET, BY COUNTRY
9.1. Introduction
9.2. South Africa
9.3. Nigeria
9.4. Algeria
9.5. Kenya
9.6. Tunisia
9.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. COMPANY PROFILES
11.1. AbbVie Inc.
11.2. Pfizer Inc.
11.3. GlaxoSmithKline plc
11.4. F. Hoffmann-La Roche Ltd
11.5. Gilead Sciences, Inc.
11.6. Johnson and Johnson
11.7. Merck & Co.
11.8. Eli Lilly and Company
11.9. Novartis AG
Companies Mentioned
- AbbVie Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Johnson and Johnson
- Merck & Co.
- Eli Lilly and Company
- Novartis AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | February 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1451.12 million |
| Forecasted Market Value ( USD | $ 1817.22 million |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Africa |
| No. of Companies Mentioned | 9 |
